Please assess the completion status of the following clinical trial:

Trial Title: Rhubarb and Angiotensin Converting Enzyme Inhibitor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients \>18 years~2. Patients with diabetic nephropathy (history of type 1 or type 2 diabetes for \> 7 years, no other cause for proteinuria listed in their medical chart). This is the definition used in most peer-reviewed trials44,45 of diabetic nephropathy. We do recognize that their proteinuria could be due to some other concomitant kidney disease but the only way to confirm that is to do a kidney biopsy which is not clinically justified.~3. Proteinuria ≥ 0.5 g/day~4. Ability to sign consent form~Exclusion Criteria:~1. Pre study GFR (see section 10.7) \< 20 ml/min~2. Renal disease of etiologies other than diabetes~3. Uncontrolled hypertension (Systolic BP \>180 mmHg and Diastolic BP \>110mm Hg)~4. Patients with history of kidney stones in past 10 years~5. Patients with active chronic liver disease (Liver enzymes ALT, AST \>2.5 times normal)~6. Patients with primary small bowel disease with malabsorption, blind loop syndrome, or jejunoileal bypass surgery (may cause unabsorbed fatty acids to combine with calcium which in turn causes too much absorption of oxalate)~7. Patients with current alcohol, illicit drug use or any other condition (eg. Psychiatry disorder) that in the opinion of the investigator may interfere with the patient's ability to comply with the study~8. Pregnant women or women of child bearing potential who are unwilling to use an adequate form of contraceptive during the course of the study (ACEI may be fetotoxic)~9. Patients with significant unstable cardiovascular disease (NYHA class III and IV)~10. Patients with active malignancy~11. Uncontrolled infections.~12. Patients with a known sensitivity to the study medications (including enalapril)~13. Patients on angiotensin II receptor blockers (ARBs)~14. Microscopic or macroscopic hematuria (to rule out kidney disease other than diabetic nephropathy)~15. Patients on any herbal supplements unwilling to discontinue them~16. Severe malnutrition (serum albumin \<2.6mg/dL)~17. Hyperkalemia at baseline, defined as serum potassium ≥ 5.5 mg/dL~18. Iodine allergy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rhubarb extract (Type: EXPERIMENTAL): will receive rhubarb extract
- placebo (Type: PLACEBO_COMPARATOR): receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).